Microbiome at the Frontier of Personalized Medicine

Mayo Clinic Proceedings

Volumn 92, Issue 12, 2017, Pages 1855-1864

  Kashyap, Purna C ^a   Chia, Nicholas ^a   Nelson, Heidi ^a   Segal, Eran ^b   Elinav, Eran ^b  

^a MAYO CLINIC   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADVERSE EVENT; CANCER PREVENTION; CANCER THERAPY; DIAGNOSIS; DRUG TARGETING; GENE SEQUENCE; GENOMICS; HEALTH CARE COST; HUMAN; HUMAN GENOME; INFECTION; INTERINDIVIDUAL VARIABILITY; MICROBIAL COMMUNITY; MICROBIAL GENETICS; MICROBIAL IDENTIFICATION; MICROBIOME; NEXT GENERATION SEQUENCING; NONHUMAN; PATHOGENESIS; PERSONALIZED MEDICINE; PHENOTYPE; PROGNOSIS; REVIEW; RISK FACTOR; TREATMENT RESPONSE; GASTROINTESTINAL TRACT; INTESTINE FLORA; MICROBIOLOGY; PHYSIOLOGY;

GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; GENOME, HUMAN; HUMANS; PRECISION MEDICINE; PROGNOSIS;

EID: 85034565152     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2017.10.004     Document Type: Review

References (79)

1. Jameson, J.L., Longo, D.L., Precision medicine—personalized, problematic, and promising. N Engl J Med 372:23 (2015), 2229–2234.
2. Marchesi, J.R., Ravel, J., The vocabulary of microbiome research: a proposal. Microbiome, 3, 2015, 31.
3. Marchesi, J.R., Adams, D.H., Fava, F., et al. The gut microbiota and host health: a new clinical frontier. Gut 65:2 (2016), 330–339.
4. Didelot, X., Bowden, R., Wilson, D.J., Peto, T.E., Crook, D.W., Transforming clinical microbiology with bacterial genome sequencing. Nat Rev Genet 13:9 (2012), 601–612.
5. Köser, C.U., Ellington, M.J., Cartwright, E.J.P., et al. Routine use of microbial whole genome sequencing in diagnostic and public health microbiology. PLoS Pathog, 8(8), 2012, e1002824.
6. Joensen, K.G., Scheutz, F., Lund, O., et al. Real-time whole-genome sequencing for routine typing, surveillance, and outbreak detection of verotoxigenic Escherichia coli. J Clin Microbiol 52:5 (2014), 1501–1510.
7. Keim, P., Van Ert, M.N., Pearson, T., Vogler, A.J., Huynh, L.Y., Wagner, D.M., Anthrax molecular epidemiology and forensics: using the appropriate marker for different evolutionary scales. Infect Genet Evol 4:3 (2004), 205–213.
8. Harris, S.R., Feil, E.J., Holden, M.T., et al. Evolution of MRSA during hospital transmission and intercontinental spread. Science 327:5964 (2010), 469–474.
9. Leopold, S.R., Goering, R.V., Witten, A., Harmsen, D., Mellmann, A., Bacterial whole-genome sequencing revisited: portable, scalable, and standardized analysis for typing and detection of virulence and antibiotic resistance genes. J Clin Microbiol 52:7 (2014), 2365–2370.
10. Veenemans, J., Overdevest, I.T., Snelders, E., et al. Next-generation sequencing for typing and detection of resistance genes: performance of a new commercial method during an outbreak of extended-spectrum-β-lactamase-producing Escherichia coli. J Clin Microbiol 52:7 (2014), 2454–2460.
11. Machado, M.P., Ribeiro-Gonçalves, B., Silva, M., Ramirez, M., Carriço, J.A., Epidemiological surveillance and typing methods to track antibiotic resistant strains using high throughput sequencing. Methods Mol Biol 1520 (2017), 331–356.
12. Schwartz, D.C., Cantor, C.R., Separation of yeast chromosome-sized DNAs by pulsed field gradient gel electrophoresis. Cell 37:1 (1984), 67–75.
13. Foxman, B., Zhang, L., Koopman, J.S., Manning, S.D., Marrs, C.F., Choosing an appropriate bacterial typing technique for epidemiologic studies. Epidemiol Perspect Innov, 2, 2005, 10.
14. Swaminathan, B., Barrett, T.J., Hunter, S.B., Tauxe, R.V., CDC PulseNet Task Force. PulseNet: the molecular subtyping network for foodborne bacterial disease surveillance, United States. Emerg Infect Dis 7:3 (2001), 382–389.
15. Kam, K.M., Luey, C.K., Parsons, M.B., et al., Vibrio parahaemolyticus PulseNet PFGE Protocol Working Group. Evaluation and validation of a PulseNet standardized pulsed-field gel electrophoresis protocol for subtyping Vibrio parahaemolyticus: an international multicenter collaborative study. J Clin Microbiol 46:8 (2008), 2766–2773.
16. Scharff, R.L., Besser, J., Sharp, D.J., Jones, T.F., Peter, G.S., Hedberg, C.W., An economic evaluation of PulseNet: a network for foodborne disease surveillance. Am J Prev Med 50:5 Suppl 1 (2016), S66–S73.
17. Price, J.R., Didelot, X., Crook, D.W., Llewelyn, M.J., Paul, J., Whole genome sequencing in the prevention and control of Staphylococcus aureus infection. J Hosp Infect 83:1 (2013), 14–21.
18. Viau, R.A., Kiedrowski, L.M., Kreiswirth, B.N., et al. A comparison of molecular typing methods applied to Enterobacter cloacae complex: hsp60 sequencing, Rep-PCR, and MLST. Pathog Immun 2:1 (2017), 23–33.
19. Salipante, S.J., SenGupta, D.J., Cummings, L.A., Land, T.A., Hoogestraat, D.R., Cookson, B.T., Application of whole-genome sequencing for bacterial strain typing in molecular epidemiology. J Clin Microbiol 53:4 (2015), 1072–1079.
20. Jolley, K.A., Maiden, M.C., Automated extraction of typing information for bacterial pathogens from whole genome sequence data: Neisseria meningitidis as an exemplar. Euro Surveill, 18(4), 2013, 20379.
21. Coll, F., McNerney, R., Guerra-Assunção, J.A., et al. A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat Commun, 5, 2014, 4812.
22. Cunningham, S.A., Chia, N., Jeraldo, P.R., et al. Comparison of whole-genome sequencing methods for analysis of three methicillin-resistant Staphylococcus aureus outbreaks. J Clin Microbiol 55:6 (2017), 1946–1953.
23. Feil, E.J., Li, B.C., Aanensen, D.M., Hanage, W.P., Spratt, B.G., eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J Bacteriol 186:5 (2004), 1518–1530.
24. Vaz, C., Francisco, A.P., Silva, M., et al. TypOn: the microbial typing ontology. J Biomed Semantics, 5(1), 2014, 43.
25. Nascimento, M., Sousa, A., Ramirez, M., Francisco, A.P., Carriço, J.A., Vaz, C., PHYLOViZ 2.0: providing scalable data integration and visualization for multiple phylogenetic inference methods. Bioinformatics 33:1 (2017), 128–129.
26. Enright, M.C., Day, N.P., Davies, C.E., Peacock, S.J., Spratt, B.G., Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol 38:3 (2000), 1008–1015.
27. Ng, L.K., Martin, I., Alfa, M., Mulvey, M., Multiplex PCR for the detection of tetracycline resistant genes. Mol Cell Probes 15:4 (2001), 209–215.
28. Wilson, M.R., Naccache, S.N., Samayoa, E., et al. Actionable diagnosis of neuroleptospirosis by next-generation sequencing. N Engl J Med 370:25 (2014), 2408–2417.
29. Scholz, C.F., Jensen, A., Development of a Single Locus Sequence Typing (SLST) scheme for typing bacterial species directly from complex communities. Methods Mol Biol 1535 (2017), 97–107.
30. Sahl, J.W., Schupp, J.M., Rasko, D.A., Colman, R.E., Foster, J.T., Keim, P., Phylogenetically typing bacterial strains from partial SNP genotypes observed from direct sequencing of clinical specimen metagenomic data. Genome Med, 7(1), 2015, 52.
31. Wattam, A.R., Abraham, D., Dalay, O., et al. PATRIC, the bacterial bioinformatics database and analysis resource. Nucleic Acids Res 42:Database issue (2014), D581–D591.
32. Zolfo, M., Tett, A., Jousson, O., Donati, C., Segata, N., MetaMLST: multi-locus strain-level bacterial typing from metagenomic samples. Nucleic Acids Res, 45(2), 2017, e7.
33. Willing, B., Halfvarson, J., Dicksved, J., et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel Dis 15:5 (2009), 653–660.
34. Willing, B.P., Dicksved, J., Halfvarson, J., et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 139:6 (2010), 1844–1854.e1841.
35. Viladomiu, M., Kivolowitz, C., Abdulhamid, A., et al. IgA-coated E. coli enriched in Crohn's disease spondyloarthritis promote TH17-dependent inflammation. Sci Transl Med, 9(376), 2017.
36. Gevers, D., Kugathasan, S., Denson, L.A., et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 15:3 (2014), 382–392.
37. Rubinstein, M.R., Wang, X., Liu, W., Hao, Y., Cai, G., Han, Y.W., Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 14:2 (2013), 195–206.
38. Buffie, C.G., Bucci, V., Stein, R.R., et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517:7533 (2015), 205–208.
39. Khanna, S., Montassier, E., Schmidt, B., et al. Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection. Aliment Pharmacol Ther 44:7 (2016), 715–727.
40. Seekatz, A.M., Rao, K., Santhosh, K., Young, V.B., Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection. Genome Med, 8(1), 2016, 47.
41. Wacklin, P., Kaukinen, K., Tuovinen, E., et al. The duodenal microbiota composition of adult celiac disease patients is associated with the clinical manifestation of the disease. Inflamm Bowel Dis 19:5 (2013), 934–941.
42. Scher, J.U., Sczesnak, A., Longman, R.S., et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife, 2, 2013, e01202.
43. Chen, J., Wright, K., Davis, J.M., et al. An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome Med, 8(1), 2016, 43.
44. Shank, E.A., Kolter, R., New developments in microbial interspecies signaling. Curr Opin Microbiol 12:2 (2009), 205–214.
45. Cornforth, D.M., Foster, K.R., Antibiotics and the art of bacterial war. Proc Natl Acad Sci U S A 112:35 (2015), 10827–10828.
46. Jones, D., Metzger, H.J., Schatz, A., Waksman, S.A., Control of gram-negative bacteria in experimental animals by streptomycin. Science 100:2588 (1944), 103–105.
47. Aigle, B., Lautru, S., Spiteller, D., et al. Genome mining of Streptomyces ambofaciens. J Ind Microbiol Biotechnol 41:2 (2014), 251–263.
48. Bachmann, B.O., Van Lanen, S.G., Baltz, R.H., Microbial genome mining for accelerated natural products discovery: is a renaissance in the making?. J Ind Microbiol Biotechnol 41:2 (2014), 175–184.
49. Donia, M.S., Cimermancic, P., Schulze, C.J., et al. A systematic analysis of biosynthetic gene clusters in the human microbiome reveals a common family of antibiotics. Cell 158:6 (2014), 1402–1414.
50. Barrangou, R., Fremaux, C., Deveau, H., et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 315:5819 (2007), 1709–1712.
51. Cong, L., Ran, F.A., Cox, D., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339:6121 (2013), 819–823.
52. Bikard, D., Euler, C.W., Jiang, W., et al. Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol 32:11 (2014), 1146–1150.
53. Clayton, T.A., Baker, D., Lindon, J.C., Everett, J.R., Nicholson, J.K., Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A 106:34 (2009), 14728–14733.
54. Sivan, A., Corrales, L., Hubert, N., et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350:6264 (2015), 1084–1089.
55. Vétizou, M., Pitt, J.M., Daillère, R., et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350:6264 (2015), 1079–1084.
56. Wallace, B.D., Wang, H., Lane, K.T., et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330:6005 (2010), 831–835.
57. Blekhman, R., Goodrich, J.K., Huang, K., et al. Host genetic variation impacts microbiome composition across human body sites. Genome Biol, 16, 2015, 191.
58. Wu, H., Esteve, E., Tremaroli, V., et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 23:7 (2017), 850–858.
59. Rubinstein, E., Camm, J., Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 49:4 (2002), 593–596.
60. Galatti, L., Giustini, S.E., Sessa, A., et al. Neuropsychiatric reactions to drugs: an analysis of spontaneous reports from general practitioners in Italy. Pharmacol Res 51:3 (2005), 211–216.
61. Rubin, B.K., Tamaoki, J., Antibiotics as Anti-Inflammatory and Immunomodulatory Agents. 2005, Birkhäuser, Boston.
62. Wallace, B.D., Redinbo, M.R., The human microbiome is a source of therapeutic drug targets. Curr Opin Chem Biol 17:3 (2013), 379–384.
63. Wang, Z., Roberts, A.B., Buffa, J.A., et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163:7 (2015), 1585–1595.
64. Kristensen, N.B., Bryrup, T., Allin, K.H., Nielsen, T., Hansen, T.H., Pedersen, O., Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Med, 8(1), 2016, 52.
65. Li, J., Sung, C.Y., Lee, N., et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci U S A 113:9 (2016), E1306–E1315.
66. Amalaradjou, M.A., Bhunia, A.K., Bioengineered probiotics, a strategic approach to control enteric infections. Bioengineered 4:6 (2013), 379–387.
67. Ruder, W.C., Lu, T., Collins, J.J., Synthetic biology moving into the clinic. Science 333:6047 (2011), 1248–1252.
68. Whitaker, W.R., Shepherd, E.S., Sonnenburg, J.L., Tunable Expression Tools Enable Single-Cell Strain Distinction in the Gut Microbiome. Cell 169:3 (2017), 538–546.e512.
69. Kelly, C.R., Kahn, S., Kashyap, P., et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 149:1 (2015), 223–237.
70. Moayyedi, P., Surette, M.G., Kim, P.T., et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149:1 (2015), 102–109.e106.
71. Halmos, E.P., Power, V.A., Shepherd, S.J., Gibson, P.R., Muir, J.G., A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 146:1 (2014), 67–75.e65.
72. Bennet SM, Böhn L, Störsrud S, et al. Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs [published online ahead of print April 17, 2017]. Gut. https://doi.org/10.1136/gutjnl-2016-313128.
73. Zeevi, D., Korem, T., Zmora, N., et al. Personalized nutrition by prediction of glycemic responses. Cell 163:5 (2015), 1079–1094.
74. Korem, T., Zeevi, D., Zmora, N., et al. Bread affects clinical parameters and induces gut microbiome-associated personal glycemic responses. Cell Metab 25:6 (2017), 1243–1253.e1245.
75. Wu, G.D., Chen, J., Hoffmann, C., et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 334:6052 (2011), 105–108.
76. Sonnenburg, E.D., Smits, S.A., Tikhonov, M., Higginbottom, S.K., Wingreen, N.S., Sonnenburg, J.L., Diet-induced extinctions in the gut microbiota compound over generations. Nature 529:7585 (2016), 212–215.
77. David, L.A., Maurice, C.F., Carmody, R.N., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505:7484 (2014), 559–563.
78. Kovatcheva-Datchary, P., Nilsson, A., Akrami, R., et al. Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of Prevotella. Cell Metab 22:6 (2015), 971–982.
79. Smits, S.A., Marcobal, A., Higginbottom, S., Sonnenburg, J.L., Kashyap, P.C., Individualized responses of gut microbiota to dietary intervention modeled in humanized mice. mSystems, 1(5), 2016.